Ascendis Pharma A/S (NASDAQ:ASND) Releases Quarterly Earnings Results, Beats Expectations By $0.11 EPS

Ascendis Pharma A/S (NASDAQ:ASND) issued its quarterly earnings data on Thursday, May 7th. The biotechnology company reported $0.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.21 by $0.11, Zacks reports. The firm had revenue of $285.45 million for the quarter, compared to analysts’ expectations of $362.47 million.

Here are the key takeaways from Ascendis Pharma A/S’s conference call:

• FDA approval of a third TransCon product (YUVIWEL/TransCon CNP) for achondroplasia, with early U.S. uptake of more than 60 children prescribed within weeks and plans for selected international early access and an EU decision expected in Q4 2026.
• Q1 revenue totaled €247M (company cited ~€197M from its lead rare‑endocrine product and €44M from SKYTROFA), with operating profit €25M (10% margin), non‑IFRS net profit €18M, €573M cash on hand, a completed Nasdaq direct listing, redemption of convertible notes, and an agreed PRV sale for $187.5M.
• The Phase II COACH data for the TransCon CNP + TransCon hGH combination showed substantially greater Week‑52 efficacy versus monotherapy (height Z‑score, limb alignment, spinal canal and arm‑span improvements), which management says could reduce or eliminate the need for invasive limb/spine surgeries.
• Management decided to discontinue internal oncology development of TransCon IL‑2 β/γ despite encouraging Phase I/II signals, signaling a strategic pullback from oncology and potential loss of internal upside for that program.

Ascendis Pharma A/S Stock Up 1.1%

Shares of Ascendis Pharma A/S stock opened at $266.72 on Wednesday. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.00 and a quick ratio of 0.72. The stock has a market cap of $16.64 billion, a price-to-earnings ratio of 30.76 and a beta of 0.39. The firm’s 50-day moving average is $233.29 and its two-hundred day moving average is $226.72. Ascendis Pharma A/S has a 1 year low of $160.86 and a 1 year high of $271.89.

Insider Activity

In other Ascendis Pharma A/S news, Director Jean Jacques Bienaime purchased 400 shares of the stock in a transaction dated Tuesday, May 26th. The stock was purchased at an average price of $237.80 per share, with a total value of $95,120.00. Following the transaction, the director owned 400 shares of the company’s stock, valued at approximately $95,120. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Flemming Steen Jensen sold 19,460 shares of the stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $238.49, for a total transaction of $4,641,015.40. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 40.00% of the company’s stock.

Institutional Trading of Ascendis Pharma A/S

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Advisory Services Network LLC purchased a new stake in shares of Ascendis Pharma A/S during the 3rd quarter worth $26,000. Arax Advisory Partners grew its stake in Ascendis Pharma A/S by 212.2% in the fourth quarter. Arax Advisory Partners now owns 153 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 104 shares during the last quarter. Global Retirement Partners LLC raised its holdings in Ascendis Pharma A/S by 111.9% in the fourth quarter. Global Retirement Partners LLC now owns 214 shares of the biotechnology company’s stock worth $46,000 after purchasing an additional 113 shares in the last quarter. GW&K Investment Management LLC lifted its position in shares of Ascendis Pharma A/S by 75.2% during the fourth quarter. GW&K Investment Management LLC now owns 226 shares of the biotechnology company’s stock valued at $48,000 after buying an additional 97 shares during the last quarter. Finally, Quadrant Capital Group LLC purchased a new stake in shares of Ascendis Pharma A/S during the third quarter valued at about $74,000.

Analyst Ratings Changes

A number of analysts have recently weighed in on the stock. Bank of America boosted their target price on shares of Ascendis Pharma A/S from $262.00 to $292.00 and gave the stock a “buy” rating in a report on Thursday, April 16th. Wedbush reissued an “outperform” rating and set a $273.00 price objective on shares of Ascendis Pharma A/S in a research note on Thursday, April 9th. Evercore restated an “outperform” rating and issued a $329.00 price target on shares of Ascendis Pharma A/S in a research report on Friday, May 15th. Jefferies Financial Group initiated coverage on shares of Ascendis Pharma A/S in a research note on Monday, March 16th. They issued a “buy” rating and a $290.00 price objective for the company. Finally, Citigroup assumed coverage on Ascendis Pharma A/S in a research report on Monday, May 18th. They set a “buy” rating and a $355.00 target price for the company. Two research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $295.39.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.